In a refreshing change of course, the FDA has approved a significant new drug. GlaxoSmithKline (NYSE:GSK) and Human Genome Sciences (Nasdaq:HGSI) announced after market close on Wednesday that the FDA had informed the companies of the approval of their application to market Benlysta for the treatment of lupus. It no doubt helped greatly that the safety/side-effect profile on Benlysta was quite clean, to say nothing of the clear clinical need for new lupus treatments. (For background reading on the FDA approval process, see A Primer On The Biotech Sector.)

9 Simple Investing Ratios You Need To Know

Where Now?
With approval in hand, the two companies will begin marketing the drug relatively soon, with a 50/50 split of costs. While there was a general expectation that HGSI and Glaxo would price Benlysta in line with drugs for multiple sclerosis or arthritis, the two companies went a bit more toward the high end of the range and Benlysta will cost about $35,000 a year (more in the first year of treatment). (For related reading, check out Pharmaceutical Phenoms: America's Best Selling Medicines.)

The FDA also gave the company a rather favorable label. While the drug is contraindicated in some of the most severe and lethal forms of lupus (those that involve the kidneys and central nervous system), the companies estimate that there are at least 200,000 eligible patients. In actual practice, though, it would be a bit surprising if more doctors did not give it a go in some less-severe cases.

The FDA's approval is partly conditional; the two companies will have to conduct a study of the drug in African-Americans. So far to date, Benlysta's results in this patient group have not been favorable, but they have not been statistically convincing either. Given that the rate of lupus is almost three times higher in people of Afro-Caribbean descent (compared to the overall incidence rate in the U.S.), that is clearly a subject that merits study.

The Market for Benlysta
All in all, it does not seem hard to imagine that Benlysta could be a $2 billion+ drug for Human Genome Sciences and Glaxo. True, the efficacy of Benlysta was not absolutely blockbuster, but it is good enough to offer significant improvements in quality of life for a sizable segment of the patient population.

Beyond lupus, though, there are other potential applications for Benlysta. The companies are already looking at follow-up studies in vasculitis and transplants, and there are possibilities in less-common diseases like Sjögren's, Waldenström's and idiopathic thrombocytopenic purpura (ITP). All told, if some of these additional indications work out, Benlysta could easily be a multibillion dollar drug. (For related reading, check out Can Savient Soar On One Specialty Drug?)

Better still, the two companies have little to worry about in terms of competition. Current therapies for lupus include steroids and antimalarials but no branded drugs with specific labeling for lupus. Immunomedics (Nasdaq:IMMU) would like to change that, and its drug has shown encouraging results in early studies, but is at least a few years from market.

The Bottom Line
Human Genome Sciences has made a remarkable transition from a basically failed genomics/sequencing concept to full-fledged biotech. It is worth wondering, though, whether HGSI is destined to stay independent. The company has two interesting late-stage compounds in testing for atherosclerosis and diabetes, and those are also partnered to Glaxo. It would seem straightforward, then, that Glaxo may be interested in buying out HGSI and gaining a 100% stake in all of these drugs.

If a deal were to come, a price well into the $30s (or higher based on Phase 3 data in those two drug candidates) would be a minimum. Of course, it does not have to be Glaxo that makes the purchase - I suspect many major pharmaceutical companies ranging from Pfizer (NYSE:PFE) to AstraZeneca (NYSE:AZN) to Forest Labs (NYSE:FRX) would at least consider the idea, as there are precious few drug companies out there today that couldn't use a virtually competition-free blockbuster product with solid economics. (For more, see Measuring The Medicine Makers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Economics

    Investing Opportunities as Central Banks Diverge

    After the Paris attacks investors are focusing on central bank policy and its potential for divergence: tightened by the Fed while the ECB pursues easing.
  2. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  3. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  4. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  5. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  6. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  7. Investing

    What’s the Difference Between Duration & Maturity?

    We look at the meaning of two terms that often get confused, duration and maturity, to set the record straight.
  8. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  9. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  10. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center